Genocea Biosciences, Inc. filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on February 9, 2023. As per the plan filed, administrative expense claims, U.S. trustee?s fees, professional compensation and expense reimbursement claims, priority tax claims and priority claims shall be paid in full in cash. Nonpriority unsecured claims of $13 million shall receive from the liquidating trustee on the plan distribution date its pro rata share of its beneficial interest in the liquidating trust.

Equity interest shall be cancelled without distribution. The plan shall be funded from available cash and sale of assets.